Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986158 Monotherapy or with Nivolumab in Advanced Cancers
NCT02419417Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2015
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of 2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol in solid tumor (advanced stage), hematologic malignancy, sponsored by Bristol Myers Squibb. Started Jun 2015; status: completed.
02
Drugs
2-(3-(3,5-dimethyltriazol-4-yl)-5-((S)-oxan-4-yl(phenyl)methyl)pyrido[3,2-b]indol-7-yl)propan-2-ol
03
Conditions
solid tumor (advanced stage)hematologic malignancy
Beyond the preview
Go deeper on NCT02419417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02419417.